Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis - Wikidata - wikimedia - TriplyDB

Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis

Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis

http://www.wikidata.org/entity/Q28546596

about

Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study.

P2860

Q52597260-B92269C4-66F8-417A-89AB-D0A3422B14D5

P2860

Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis

http://www.wikidata.org/entity/Q28546596

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@ast

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@en

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@nl

type

label

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@ast

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@en

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@nl

prefLabel

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@ast

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@en

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@nl

P1433

Q28546596-CB1FD9CA-33A7-4F4E-AEF8-787C066E0682

P1476

Q28546596-70FB8164-3279-4565-BC05-263D29BAF02C

P2093

Q28546596-369F4E42-DFB0-4D58-AFA6-9B1F503FFC10

Q28546596-48E181DA-96C3-4215-9854-5CD904F7D172

Q28546596-5EDCE8CA-261C-4444-8F7C-667F07CDD51D

Q28546596-5EFFAC49-3FC6-4DB7-A79C-B1AAB5E20995

Q28546596-7A904F32-314D-423C-A35A-B45EEBB8FD56

Q28546596-83D1FB18-8F5E-42BA-8564-FABCBDDDBC53

Q28546596-9BFC0CE8-5B70-4645-A577-0DAAFE7E640B

Q28546596-E5EAA88A-F558-41DC-9D23-76EDE0D76138

P2860

Q28546596-0AA2BF5D-D8D9-4BF6-A048-CA77164F6EF6

Q28546596-0D09277B-8CFE-4AC1-80A1-0F9455B2E659

Q28546596-0FB2C736-F2E5-42BC-855C-17F51FEAFA86

Q28546596-197D99A0-6372-465F-A480-B7ADBDB56F9A

Q28546596-278A2D99-106B-4E05-9097-66FA5E15F30E

Q28546596-32F29752-E7A3-42CA-ACD7-84E59CF7BEB3

Q28546596-40A9F308-11A2-432E-A884-135B25287412

Q28546596-59AABDE7-FDEB-418E-BEB1-68DF4281663E

Q28546596-78BE714D-7D5F-4998-90B5-9A0782298BA8

Q28546596-7E5D0E05-A075-4242-824C-190C40D69588

P304

Q28546596-A4484E81-5D8F-4C45-BA24-D9DC7BD90DCB

P31

Q28546596-2D600A79-15D1-4308-B615-A7C4C3BB9923

P356

Q28546596-6B78278A-6BCE-4486-A964-0208F440B4A5

P407

Q28546596-F1490F6E-7C2D-4EBF-B46B-E3FF8327685C

P433

Q28546596-A858646B-FEDB-4B22-93BC-A487C585BE5E

P478

Q28546596-6825BB1A-A26D-4498-9575-F3316106D963

P50

Q28546596-3ACAB372-54F4-4C8F-B671-4CB436A5E203

Q28546596-D5354F94-08EC-4B51-A3CF-91D0E9915CBF

P577

Q28546596-B141E36C-381C-4CCC-B5F8-5CC4ECB92B59

P5875

Q28546596-3AE63DAA-D9DD-4115-A28C-19625C100170

P698

Q28546596-69CAF680-9838-439C-B1A4-21D5676C517E

P932

Q28546596-C482414D-D3A9-489E-89D3-4475F80AA7AE

P356

JOURNAL.PONE.0131864

P1433

P1476

Predictors of Switching Anti-T ...... ts with Ankylosing Spondylitis

@en

P2093

Dong-Jin Park

http://www.w3.org/2001/XMLSchema#string

Jeong-Won Lee

http://www.w3.org/2001/XMLSchema#string

Ji-Eun Kim

http://www.w3.org/2001/XMLSchema#string

Ji-Hyoun Kang

http://www.w3.org/2001/XMLSchema#string

Kyung-Eun Lee

http://www.w3.org/2001/XMLSchema#string

Shin-Seok Lee

http://www.w3.org/2001/XMLSchema#string

Yi-Rang Yim

http://www.w3.org/2001/XMLSchema#string

Yong-Wook Park

http://www.w3.org/2001/XMLSchema#string

P2860

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.

P304

e0131864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0131864

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281823219

http://www.w3.org/2001/XMLSchema#string

P698

26176701

http://www.w3.org/2001/XMLSchema#string

P932

4503780

http://www.w3.org/2001/XMLSchema#string